Healthia Beheer

Beheer criteriumcontroles 3/4

De CEO Healthia is Wes Coote, benoemd in Apr2019, heeft een ambtstermijn van 4.67 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 660.60K, bestaande uit 60.2% salaris en 39.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.42% van de aandelen van het bedrijf, ter waarde A$ 3.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 5.6 jaar.

Belangrijke informatie

Wes Coote

Algemeen directeur

AU$660.6k

Totale compensatie

Percentage CEO-salaris	60.2%
Dienstverband CEO	4.7yrs
Eigendom CEO	1.4%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

Healthia Limited (ASX:HLA) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Sep 17

Healthia (ASX:HLA) Is Increasing Its Dividend To AU$0.025

Sep 01

I Ran A Stock Scan For Earnings Growth And Healthia (ASX:HLA) Passed With Ease

Aug 17

Is Now An Opportune Moment To Examine Healthia Limited (ASX:HLA)?

May 19

Is Healthia (ASX:HLA) A Risky Investment?

Apr 19

With EPS Growth And More, Healthia (ASX:HLA) Is Interesting

Apr 03

Announcing: Healthia (ASX:HLA) Stock Increased An Energizing 108% In The Last Year

Mar 19

Insider Buying: The Healthia Limited (ASX:HLA) Independent Non-Executive Director Just Bought 4.7% More Shares

Mar 06

What Kind Of Shareholders Hold The Majority In Healthia Limited's (ASX:HLA) Shares?

Feb 26

Is There Now An Opportunity In Healthia Limited (ASX:HLA)?

Feb 09

Healthia Limited's (ASX:HLA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 19

Why Dividend Hunters Love Healthia Limited (ASX:HLA)

Dec 29

Did You Miss Healthia's (ASX:HLA) 13% Share Price Gain?

Dec 10

We're Not So Sure You Should Rely on Healthia's (ASX:HLA) Statutory Earnings

Nov 20

Analyse CEO-vergoeding

Hoe is Wes Coote's beloning veranderd ten opzichte van Healthia's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	AU$661k	AU$398k	AU$5m
Mar 31 2023	n/a	n/a	AU$3m
Dec 31 2022	n/a	n/a	AU$781k
Sep 30 2022	n/a	n/a	-AU$1m
Jun 30 2022	AU$516k	AU$345k	-AU$3m
Mar 31 2022	n/a	n/a	-AU$2m
Dec 31 2021	n/a	n/a	AU$161k
Sep 30 2021	n/a	n/a	AU$3m
Jun 30 2021	AU$400k	AU$306k	AU$5m
Mar 31 2021	n/a	n/a	AU$6m
Dec 31 2020	n/a	n/a	AU$7m
Sep 30 2020	n/a	n/a	AU$5m
Jun 30 2020	AU$313k	AU$225k	AU$3m
Mar 31 2020	n/a	n/a	AU$1m
Dec 31 2019	n/a	n/a	AU$271k
Sep 30 2019	n/a	n/a	-AU$483k
Jun 30 2019	AU$226k	AU$176k	-AU$1m

Compensatie versus markt: De totale vergoeding ($USD 439.78K ) Wes } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 670.85K ).

Compensatie versus inkomsten: De vergoeding van Wes is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Wes Coote

4.7yrs

Tenure

AU$660,599

Compensatie

Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wesley Coote	Group MD	4.7yrs	AU$660.60k	1.42% A$ 3.6m
Damien Peters	Group Chief Financial Officer	less than a year	AU$319.83k	geen gegevens
Darren Stewart	Director of Podiatry & Executive Director	no data	AU$115.34k	6.4% A$ 16.1m
Lisa Roach	Group Chief Partnerships Officer & Executive Director	less than a year	AU$391.84k	0.75% A$ 1.9m
Colin Kangisser	CEO of Eyes & Ears Division and Director	2.7yrs	AU$368.92k	3.66% A$ 9.2m
Roy Walker	Chief Executive Officer of Bodies	less than a year	AU$314.24k	geen gegevens
Dean Hartley	Chief Technology Officer	1.9yrs	AU$261.49k	2.49% A$ 6.3m
Julia Murfitt	General Counsel & Company Secretary	1.8yrs	geen gegevens	geen gegevens
Anthony Ganter	Group Chief Business Development & Strategy Officer	no data	AU$341.32k	0% A$ 0
Kerrie Evans	Group Chief Education & Research Officer	no data	geen gegevens	geen gegevens
Aaron Kangisser	Chief Operating Officer of Eyes & Ears Division	less than a year	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van HLA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wesley Coote	Group MD	4.7yrs	AU$660.60k	1.42% A$ 3.6m
Darren Stewart	Director of Podiatry & Executive Director	5.6yrs	AU$115.34k	6.4% A$ 16.1m
Lisa Roach	Group Chief Partnerships Officer & Executive Director	1.7yrs	AU$391.84k	0.75% A$ 1.9m
Colin Kangisser	CEO of Eyes & Ears Division and Director	2.7yrs	AU$368.92k	3.66% A$ 9.2m
Glen Richards	Non-Executive Chairman	5.6yrs	AU$130.00k	5.67% A$ 14.3m
Paul Wilson	Independent Non-Executive Director	5.6yrs	AU$80.00k	2.51% A$ 6.3m
Lisa Dalton	Independent Non-Executive Director	5.6yrs	AU$80.00k	0.034% A$ 85.2k

5.6yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van HLA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Healthia Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Healthia Limited Announces Board Changes

Healthia Limited Appoints Damien Peters as Group Chief Financial Officer

Healthia Announces Resignation of Chris Banks as CFO

Independent Non-Executive Director recently bought AU$85k worth of stock

Less than half of directors are independent

Healthia Limited, Annual General Meeting, Nov 23, 2022

Recent updates

Healthia Limited Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to AU$1.80

Pacific Equity Partners made an offer to acquire Healthia Limited from MA Financial Group Limited (ASX:MAF), Wilson Asset Management (International) Pty Ltd. and Regal Partners Limited (ASX:RPL) for an offer per share of AUD 1.8.

Harold Bidco Pty Ltd made an offer to acquire Healthia Limited for an offer per share of AUD 1.8.

New major risk - Financial position

Full year 2023 earnings released: EPS: AU$0.046 (vs AU$0.028 loss in FY 2022)

Price target decreased by 8.1% to AU$2.26

Healthia Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

New minor risk - Market cap size

First half 2023 earnings released: EPS: AU$0.03 (vs AU$0.001 loss in 1H 2022)

Healthia Limited (ASX:HLA) agreed to acquire Kosmac & Clemens Optometrists.

Healthia Limited Appoints Damien Peters as Group Chief Financial Officer

Calculating The Fair Value Of Healthia Limited (ASX:HLA)

Healthia Announces Resignation of Chris Banks as CFO

Independent Non-Executive Director recently bought AU$85k worth of stock

Healthia Limited (ASX:HLA) completed the acquisition of Corio Bay Health Group.

Less than half of directors are independent

Healthia Limited (ASX:HLA) acquired Watsonia Physiotherapy.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Healthia Limited, Annual General Meeting, Nov 23, 2022

Healthia Limited (ASX:HLA) entered into binding agreement to acquire Corio Bay Health Group.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Healthia Limited Determines Not to Declare the Payment of A Final Dividend for 2022

Price target decreased to AU$2.36

Healthia Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Consensus EPS estimates fall by 55%

Healthia Limited Provides Financial Guidance for the Year Ending June 30, 2022

Now 22% undervalued after recent price drop

Less than half of directors are independent

Healthia Limited Announces Board Changes

Board Member recently sold AU$52k worth of stock

Consensus EPS estimates fall by 70%

First half 2022 earnings: EPS and revenues miss analyst expectations

Healthia (ASX:HLA) Has Re-Affirmed Its Dividend Of AU$0.02

Healthia Limited Announces Dividend on HLA - ORDINARY FULLY PAID for the Six Months Ended 31 Dec. 2021, Payable on 24 March 2022

Healthia Limited Recommends Interim Dividend, Payable on March 22, 2022

Healthia Limited to Report First Half, 2022 Results on Feb 28, 2022

Healthia Limited (ASX:HLA) entered into binding agreement to acquire Mornington Peninsula Family Physiotherapy.

Board Member recently bought AU$64k worth of stock

Here's Why Healthia Limited's (ASX:HLA) CEO May Deserve A Raise

Price target increased to AU$2.55

Healthia Limited has completed a Follow-on Equity Offering in the amount of AUD 22.268376 million.

Earnings Tell The Story For Healthia Limited (ASX:HLA) As Its Stock Soars 30%

Healthia Limited (ASX:HLA) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Investor sentiment improved over the past week

Healthia (ASX:HLA) Is Increasing Its Dividend To AU$0.025

Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.043 in FY 2020)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Healthia (ASX:HLA) Passed With Ease

Healthia Limited (ASX:HLA) entered into a binding agreement to acquire John Holme Optometrist Mareeba.

Is Now An Opportune Moment To Examine Healthia Limited (ASX:HLA)?

Healthia Limited (ASX:HLA) agreed to acquire The Eyecare Place for AUD 0.62 million.

Is Healthia (ASX:HLA) A Risky Investment?

With EPS Growth And More, Healthia (ASX:HLA) Is Interesting

Announcing: Healthia (ASX:HLA) Stock Increased An Energizing 108% In The Last Year

Healthia Limited (ASX:HLA) completed the acquisition of Sandringham Sports Physio.

Insider Buying: The Healthia Limited (ASX:HLA) Independent Non-Executive Director Just Bought 4.7% More Shares

Independent Non-Executive Director recently bought AU$96k worth of stock

First half 2021 earnings released: EPS AU$0.071 (vs AU$0.011 in 1H 2020)

Revenue beats expectations

Healthia Limited (ASX:HLA) acquired 4 physiotherapy clinics for AUD 1.3 million.

What Kind Of Shareholders Hold The Majority In Healthia Limited's (ASX:HLA) Shares?

Is There Now An Opportunity In Healthia Limited (ASX:HLA)?

Healthia Limited (ASX:HLA) completed the acquisition of The Physio Clinic for AUD 2 million.

Investor sentiment improved over the past week

New 90-day high: AU$1.90

Healthia Limited's (ASX:HLA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Investor sentiment improved over the past week